3.1 IRB/IEC Functions and Oversight

Institutional Review Boards (IRB) and Independent Ethics Committees (IEC)

The cornerstone of clinical research ethics is the independent review of research protocols involving human subjects. In the United States, this reviewing body is typically referred to as an Institutional Review Board (IRB). Internationally, particularly under ICH GCP guidelines, it is known as an Independent Ethics Committee (IEC). While the terminology differs slightly depending on the regulatory framework, the core mandate remains identical: to safeguard the rights, safety, and well-being of all human research participants.

Regulatory bodies rely on IRBs and IECs to act as the primary gatekeepers for ethical research conduct. Before any clinical trial can commence, the investigator or sponsor must obtain written and dated approval or favorable opinion from the IRB/IEC for the trial protocol, written informed consent form, consent form updates, subject recruitment procedures (e.g., advertisements), and any other written information to be provided to subjects.

IRB Membership and Composition

To ensure a balanced, comprehensive, and unbiased review of clinical research, regulatory guidelines (such as FDA 21 CFR Part 56 and ICH GCP E6(R2) Section 3) mandate specific composition requirements for an IRB/IEC.

The board must consist of a reasonable number of members, who collectively have the qualifications and experience to review and evaluate the science, medical aspects, and ethics of the proposed trial. Specifically, the minimum requirements dictate that an IRB must have:

1. At least five members: This is the absolute minimum, though many institutional IRBs have significantly more members to ensure quorums can be easily met and diverse expertise is available.
2. At least one member whose primary area of interest is in a scientific area: This individual (often a physician, pharmacist, or PhD researcher) is critical for evaluating the scientific merit, study design, and potential risks of the protocol.
3. At least one member whose primary area of interest is in non-scientific areas: Examples include ethicists, lawyers, or clergy. Their role is to ensure the research is evaluated not just on its scientific merit, but on its ethical implications, fairness, and the clarity of subject-facing materials.
4. At least one member who is independent of the institution/trial site: This unaffiliated member (sometimes a community representative) provides an objective perspective, free from institutional conflicts of interest or pressures to approve research that might financially benefit the site.

Types of IRB Review

Clinical research protocols are not a monolith; they range from anonymous surveys to first-in-human gene therapies. To manage this spectrum, IRBs utilize different levels of review based on the degree of risk posed to participants. The concept of "minimal risk" is central to determining the appropriate review pathway. Minimal risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.

Continuing Review and Ongoing Oversight

The IRB's responsibility does not end with the initial approval of a protocol. Ongoing oversight is legally required to ensure the continuous safety of participants and the ethical conduct of the trial.

Continuing Review: For ongoing studies, the IRB must conduct a continuing review of research at intervals appropriate to the degree of risk, but not less than once per year. The investigator must submit a progress report detailing the number of subjects enrolled, a summary of adverse events, any protocol deviations, and any new literature or findings that might affect the study's risk/benefit ratio. If the IRB does not renew approval before the expiration date, all research activities (including subject treatments and data collection) must halt immediately, unless stopping the intervention would severely harm current participants.

Protocol Amendments: Investigators cannot implement any deviation from, or changes of, the protocol without prior review and documented approval from the IRB. The only exception is when a change is necessary to eliminate an immediate hazard to trial subjects. In such cases, the implemented deviation must be reported to the IRB, the sponsor, and regulatory authorities as soon as possible.

Unanticipated Problems and Protocol Deviations: Clinical Research Coordinators (CRCs) play a crucial role in maintaining IRB compliance. If a protocol deviation occurs (e.g., a subject misses a required safety lab draw or is given an incorrect drug dose), it must be documented and, depending on institutional policy and the severity of the deviation, reported to the IRB. Furthermore, investigators are obligated to promptly report any unanticipated problems involving risks to subjects or others (UPIRSOs) to the IRB. This includes serious and unexpected adverse events related to the study intervention.

The Clinical Research Coordinator's Role with the IRB

The CRC is often the primary liaison between the investigator and the IRB. Responsibilities typically include preparing the initial submission packet (protocol, informed consent form, investigator's brochure, recruitment materials), drafting responses to IRB stipulations or questions, submitting prompt reports of adverse events and deviations, and ensuring continuing review applications are filed well before expiration deadlines. A CRC's meticulous attention to IRB documentation ensures the trial remains compliant and, most importantly, that participant safety is actively monitored.